Cryo-Cell International, Inc. (CCEL) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
CCEL's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
CCEL Revenue Analysis (2013–2024)
As of March 1, 2026, Cryo-Cell International, Inc. (CCEL) generated trailing twelve-month (TTM) revenue of $31.7 million, reflecting slight decline in growth of -3.0% year-over-year. The most recent quarter (Q3 2025) recorded $7.8 million in revenue, down 1.3% sequentially.
Looking at the longer-term picture, CCEL's 5-year compound annual growth rate (CAGR) stands at +0.1%, indicating moderate growth over time. The company achieved its highest annual revenue of $32.0 million in 2024, representing a new all-time high.
Revenue diversification analysis shows CCEL's business is primarily driven by Processing And Storage Fees (99%), Public Banking (1%), and Product (0%). With over half of revenue concentrated in Processing And Storage Fees, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including SOLV (+0.9% YoY), HCSG (+6.3% YoY), and AMN (-8.5% YoY), CCEL has underperformed the peer group in terms of revenue growth. Compare CCEL vs SOLV →
Peer Comparison
Compare CCEL's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CCELCurrent | $32M | -3.0% | +0.1% | 10.9% | |
| SOLV | $8.3B | +0.9% | - | 26.2% | |
| HCSG | $1.8B | +6.3% | +0.9% | 2.6% | |
| AMN | $3.0B | -8.5% | +6.1% | -3.4% | |
| CCRN | $1.3B | -22.1% | +10.3% | -1.3% | |
| AMS | $28M | +17.8% | +6.6% | -9.9% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $32.0M | +2.0% | $24.0M | 75.2% | $3.5M | 10.9% |
| 2023 | $31.3M | +3.3% | $22.9M | 73.1% | $-12,304,032 | -39.3% |
| 2022 | $30.3M | +5.0% | $21.5M | 71.0% | $4.0M | 13.3% |
| 2021 | $28.9M | -7.3% | $19.9M | 68.9% | $4.0M | 13.9% |
| 2020 | $31.1M | -2.1% | $21.5M | 69.0% | $7.7M | 24.6% |
| 2019 | $31.8M | +8.9% | $21.8M | 68.5% | $5.1M | 15.9% |
| 2018 | $29.2M | +15.1% | $20.7M | 70.8% | $5.2M | 17.8% |
| 2017 | $25.4M | +9.8% | $18.7M | 73.5% | $5.0M | 19.7% |
| 2016 | $23.1M | +9.7% | $17.4M | 75.0% | $434K | 1.9% |
| 2015 | $21.1M | +4.8% | $15.5M | 73.3% | $2.9M | 13.9% |
See CCEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CCEL Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CCEL vs AGIO
See how CCEL stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CCEL's revenue growth accelerating or slowing?
CCEL revenue growth slowed to -3.0%, below the 5-year CAGR of +0.1%. TTM revenue is $32M. The deceleration marks a shift from historical growth rates.
What is CCEL's long-term revenue growth rate?
Cryo-Cell International, Inc.'s 5-year revenue CAGR of +0.1% reflects the variable expansion pattern. Current YoY growth of -3.0% is near this long-term average.
How is CCEL's revenue distributed by segment?
CCEL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.